6533b821fe1ef96bd127c2a8

RESEARCH PRODUCT

Sedation During Neurocritical Care

Vicent QuilisVicent QuilisFederico BilottaRafael BadenesVicente ChisbertNieves Vanaclocha

subject

medicine.medical_specialtymedicine.drug_classSedationCritical Care and Intensive Care Medicinelcsh:RD78.3-87.303 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineKetamineDexmedetomidineIntensive care medicinebusiness.industryNeurointensive careneurointensive care unitReview articleneurological wakeup testAnesthesiology and Pain Medicineneurocritical carelcsh:AnesthesiologySedativesedative agentsMidazolamNeurology (clinical)medicine.symptombusinessPropofol030217 neurology & neurosurgerymedicine.drug

description

AbstractSedation is an essential therapeutic strategy in the care of neurocritical patients. Intravenous sedative agents are the most widely used, with promising alternatives (dexmedetomidine, ketamine, and volatile agents) to propofol and midazolam arising. Studies designed to evaluate superiority and avoid biases are required. A neurological awakening test is safe in most patients. Potential risks and benefits of limiting deep sedation and daily interruption of sedation in these patients remain unclear. The aim of this review was to report recent clinical evidence on sedation in this subgroup of patients, focusing on its effects on clinical prognosis.

https://doi.org/10.1055/s-0039-1688897